Quantcast
Last updated on April 16, 2014 at 11:25 EDT

Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems

April 11, 2013

Newly Created Position to Strengthen Clinical Research

WOODCLIFF LAKE, N.J., April 11, 2013 /PRNewswire/ — Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems. In this role, Dr. Kramer will be responsible for the approval of protocol designs of pivotal studies to achieve timely regulatory approval of competitive labels for new products, indications and life-cycle extensions. This includes the selection of study regions and clinical sites. He also will provide oversight of the design of Proof of Concept (POC) Studies for each of Eisai’s Product Creation Units.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

In addition to these new responsibilities, Dr. Kramer will continue to serve as president of the Neuroscience and General Medicine Product Creation Unit, a position he has held since July 2009. In this capacity, he is responsible for overseeing the full product creation cycle from discovery through regulatory approval of innovative projects in the neuroscience and general medicine areas.

Dr. Kramer joined Eisai in 2007 as executive vice president of Global Clinical Research and was soon promoted to the additional role of COO of Eisai Medical Research. Upon the establishment of Eisai Product Creation Systems in 2009, he accepted a dual appointment as president of the Neuroscience and General Medicine Product Creation Unit and also the Scientific and Operational Clinical Support (SOCS) Core Functional Unit. He held the SOCS position until mid-2010.

Dr. Kramer is a Fellow of the American Board of Psychiatry and Neurology. He currently serves as the industry representative on the Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration and is on the Board of Directors of the American Society for Experimental NeuroTherapeutics (ASENT). Dr. Kramer also has been appointed to the newly established Scientific Leadership Advisory Council of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Dr. Kramer received his MD from Hahnemann Medical College. He completed his internship in internal medicine at the University of California at Irvine and his residency in neurology at the University of Virginia. Dr. Kramer also holds a Bachelor of Arts from Lycoming College, where he has since been named to the Board of Trustees.

Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.

Media Inquiries
Suzanne Grogan
201-746-2083
suzanne_grogan@eisai.com

SOURCE Eisai Inc.


Source: PR Newswire